On October 24 2025, Charles River Laboratories International, Inc. (CRL) announced a new collaboration with the Francis Crick Institute to advance antibody‑drug conjugate (ADC) discovery and development. The partnership is designed to streamline the entire ADC pipeline—from antibody generation to conjugation, in‑vitro profiling, and preclinical studies—by integrating the expertise of both organizations.
The collaboration will leverage phage‑display libraries for high‑affinity, target‑specific antibody generation and will employ CRL’s Retrogenix™ platform to evaluate off‑target interactions early in the development process. By jointly managing the end‑to‑end workflow, the two companies aim to reduce timelines and increase efficiency in bringing promising ADC candidates to clinical testing.
Chief Scientific Officer Justin Bryans of CRL emphasized that the partnership “enables the development of smarter, safer therapeutics that are more likely to succeed in the clinic.” Director of Translation at the Crick, David Allen, added that the collaboration “marks a powerful convergence of innovation and execution.” The alliance represents a strategic expansion into the rapidly growing ADC market, positioning CRL to capture new opportunities in targeted therapy development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.